IMVT logo

IMVT Immunovant, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$31.77
-0.75 (-2.31%)

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a ke…

Market Cap: $6.57Bimmunovant.com

Price

No data yet.

Social Signal Score

49
5d
—
30d
55
4 mentions
—
60d
48
7 mentions
—
90d
44
9 mentions
—
news: 8 · rss: 1

Analyst Ratings

23 analysts
Buyconsensus
Strong Buy 0Buy 18Hold 4Sell 1Strong Sell 0
Avg price target$43.67+37.5%
Low $40Median $41High $50
Current Consensus

Revenue

$0.00
$0.00$2.37M$4.73M$7.09M
Jun 2018Sep 2026

Analyst Estimates

FY2026
$-2.61
$-2.85–$-2.48
11 analysts
FY2027
$-2.39
$-2.92–$-2.08
8 analysts
FY2028
$-2.43
$-3.14–$-1.29
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Eric Venker
Sector
Healthcare
Industry
Biotechnology
Employees
315
Beta
0.84
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
33.08
immunovant.com